NeuroSense partners with PhaseV on upcoming phase 3 ALS trial
Betsy Goodfellow | May 16, 2024 | News story | Research and Development | NeuroSense, Neurology, als, clinical trials
NeuroSense has announced that it has partnered with PhaseV for its upcoming phase 3 trial of PrimeC as a treatment of amyotrophic lateral sclerosis (ALS).
As part of this collaboration, PhaseV has undertaken an independent analysis of NeuroSense’s PARADIGM phase 2b study which used a causal machine learning (ML) and ‘predicts a high probability of success in multiple subgroups for the planned phase 3 trial of PrimeC as a treatment for ALS’, according to the company’s press release.
NeuroSense has previously reported positive efficacy and safety data from its phase 2b trial, during which PrimeC showed a statistically significant 37% slowing of disease progression in ALS, as well as a statistically significant 43% slowing of disease progression in high-risk patients after six months of treatment.
Alon Ben-Noon, chief executive officer of NeuroSense, commented: “There remains a critical need for new innovative approaches to address this devastating neurodegenerative disease. Our recently announced subgroup analysis from the PARADIGM study is very encouraging and suggests the potential of PrimeC to change this reality. Through our initial collaboration with PhaseV, we gained an even greater understanding of the effect of PrimeC across multiple patient subgroups. We will apply these insights to optimise the design of our phase 3 study with the aim of maximising meaningful clinical results that will differentiate PrimeC in the market. We plan to continue to collaborate with PhaseV as we develop our phase 3 trial.”
Betsy Goodfellow
Related Content
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
